Hatay Pharmaceutical Joint Stock CO Pharmaceutical Import Profile — Vietnam (DGFT 2022–2026)

Name: Hatay Pharmaceutical Joint Stock CO Pharmaceutical Import Records from India — 2 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hatay Pharmaceutical Joint Stock CO — Pharmaceutical Importer Profile (2026) | 2 Products, $1.2M Trade | TransData Nexus

Hatay Pharmaceutical Joint Stock CO

Pharmaceutical Importer · Vietnam · Diabetes & Endocrine Focus · $1.2M Total Trade · DGFT Verified

Hatay Pharmaceutical Joint Stock CO is a pharmaceutical importer based in Vietnam with a total trade value of $1.2M across 2 products in 2 therapeutic categories. Based on 26 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hatay Pharmaceutical Joint Stock CO sources from 16 verified Indian suppliers, with Wockhardt Limited accounting for 71.2% of imports.

Hatay Pharmaceutical Joint Stock CO — Import Portfolio & Supplier Network

Hatay Pharmaceutical Joint Stock CO import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hatay Pharmaceutical Joint Stock CO?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Wockhardt Limited	$3.4M	107	71.2%
Swiss Parenterals Limited	$298.6K	9	6.2%
Stallion Laboratories Private Limited

What Formulations Does Hatay Pharmaceutical Joint Stock CO Import?

Formulation	Value	Ships
Wosulin 30/70 40iu/ML, 10ML vial	$300.0K	9
Wosulin 30/70 cartridge 100iu 3ML 1s	$236.1K	5
Meritaxi 1GM INJ with wfi 10ML -mfg.	$200.0K	4
Glaritus dispopen-2	$180.2K	5
Wosulin 30/70 vial 40iu 10ML -green	$150.0K	3
Wosulin 30/70 vial 40iu 10ML (+19830 vials -free goods of no commercial value	$150.0K	3
Glaritus dispopen 100iu 3ML 1s -green	$126.4K	3
Glaritus dispopen - 2 (insulin glargineinjection 100iu/ML, 3ML)	$119.7K	4
Pharmaceutical goods/harmless medicinesfor human use - pdsolone-125 MG (detailas per invoice) (100000 boxes	$110.0K	3
Wosulin 30/70 dispopen 100iu 3ML 1s	$104.5K	3
Wosulin 30/70 cartridge 100iu 3ML 1s -green card no.pune-6 dated 28.03.2024 valid upto	$100.4K	3
Meritaxi 1g with wfi (10ML) -mfg. by	$100.0K	2
Wosulin 30 70 40iu ML 10ML vial biphasic isophane insulin injection	$100.0K	2
Glaritus cartridge 100iu ML 3ML 1 s insulin glargine injection BP 100iu ML	$100.0K	2
Meritaxi 1g with wfi 10ML - manufacturing . by	$100.0K	2

Hatay Pharmaceutical Joint Stock CO imports 114 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Insulin	Diabetes & Endocrine	$1.0M	20	1.3%	16
2	Taila	Ayurvedic & Herbal Products	$207.8K	6	2.7%	6

Hatay Pharmaceutical Joint Stock CO imports 2 pharmaceutical products across 2 categories into Vietnam totaling $1.2M.

Hatay Pharmaceutical Joint Stock CO — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hatay Pharmaceutical Joint Stock Company is a Vietnamese pharmaceutical importer and buyer specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in Vietnam's pharmaceutical distribution network, sourcing a diverse range of products to meet the country's healthcare needs. While specific details about its headquarters and parent company are not publicly disclosed, Hatay Pharmaceutical Joint Stock Company is recognized for its significant contributions to the Vietnamese pharmaceutical market.

The company's operations are characterized by a strategic focus on importing pharmaceutical products from India, reflecting a robust trade relationship between the two nations. This emphasis on Indian imports underscores Hatay Pharmaceutical Joint Stock Company's commitment to providing high-quality medications to the Vietnamese market. The company's role extends beyond mere distribution; it serves as a critical link in the supply chain, ensuring the availability of essential pharmaceutical products across Vietnam.

2Distribution Network

Hatay Pharmaceutical Joint Stock Company's distribution network is designed to ensure efficient delivery of pharmaceutical products throughout Vietnam. While specific details regarding warehouse locations and logistics capabilities are not publicly available, the company's extensive import activities suggest a well-established infrastructure capable of handling a diverse product portfolio. The network's geographic coverage likely spans major urban centers and extends to rural areas, facilitating widespread access to imported pharmaceutical products.

The company's logistics operations are presumably optimized to maintain the integrity and quality of pharmaceutical products during transit. This includes adherence to temperature control requirements, secure storage conditions, and compliance with Vietnamese regulations governing pharmaceutical distribution. The effectiveness of this distribution network is crucial for meeting the healthcare demands of the Vietnamese population and ensuring timely availability of imported medications.

3Industry Role

In Vietnam's pharmaceutical supply chain, Hatay Pharmaceutical Joint Stock Company functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company bridges the gap between foreign manufacturers and the Vietnamese market. This role is essential for introducing a variety of pharmaceutical products to Vietnam, thereby enhancing the diversity and availability of medications.

The company's position as a wholesaler allows it to supply pharmaceutical products to various stakeholders, including hospitals, clinics, pharmacies, and government health programs. This broad distribution capability underscores Hatay Pharmaceutical Joint Stock Company's significance in the Vietnamese healthcare sector, contributing to the overall accessibility and affordability of essential medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hatay Pharmaceutical Joint Stock CO

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hatay Pharmaceutical Joint Stock Company's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.2 million USD from India across 26 shipments. The top five products imported are Insulin ($1.0 million, 1.3% share) and Taila ($208,000, 2.7% share), indicating a focused product portfolio. This concentration suggests a strategic choice to specialize in specific therapeutic areas, particularly in diabetes and endocrine treatments, which constitute 82.8% of the imported products.

The supplier base is also concentrated, with Wockhardt Limited accounting for 71.2% of the total import value. This reliance on a single supplier could pose risks related to supply chain disruptions, pricing fluctuations, and dependency on the supplier's production capabilities. However, the stability of this relationship, as evidenced by 107 shipments, indicates a well-established and reliable partnership.

2Supply Chain Resilience

The resilience of Hatay Pharmaceutical Joint Stock Company's supply chain is closely tied to its dependency on Indian suppliers, particularly Wockhardt Limited. While the company's focus on a single supplier may streamline operations and ensure consistency, it also exposes the supply chain to potential vulnerabilities. These include risks associated with geopolitical tensions, regulatory changes, and logistical challenges that could impact the timely delivery of products.

Importing Pharmaceuticals into Vietnam — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Vietnam

1Regulatory Authority & Framework

In Vietnam, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Health (MOH). The MOH is responsible for formulating and implementing policies related to drug registration, importation, and distribution. Key legislation governing pharmaceutical imports includes the Law on Pharmacy and various decrees and circulars issued by the MOH, which outline the procedures for drug registration, quality control, and market authorization.

The marketing authorization pathway for Indian generics involves several steps. Initially, the product must undergo a registration process with the MOH, which includes submission of comprehensive documentation such as clinical trial data, manufacturing details, and quality control measures. Upon approval, the product is granted a marketing authorization, allowing it to be imported and distributed within Vietnam. This process ensures that all pharmaceutical products meet the safety, efficacy, and quality standards set by Vietnamese authorities.

2Import Licensing & GMP

Import licensing requirements in Vietnam are stringent, necessitating that all pharmaceutical importers, including Hatay Pharmaceutical Joint Stock Company, obtain an import license from the Ministry of Health. This license is contingent upon the importer's compliance with various criteria, including adherence to Good Manufacturing Practice (GMP) standards. The MOH recognizes GMP certifications from reputable international bodies such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Hatay Pharmaceutical Joint Stock CO — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hatay Pharmaceutical Joint Stock Company's product strategy focuses on importing pharmaceutical products in the therapeutic areas of diabetes and endocrine disorders, as well as Ayurvedic and herbal products. This focus is driven by the significant demand for treatments in these categories within the Vietnamese market. The prevalence of diabetes and endocrine disorders in Vietnam has led to a sustained need for effective medications, positioning these therapeutic areas as strategic priorities for the company.

The importation of Ayurvedic and herbal products reflects a growing consumer interest in alternative and traditional medicine. This segment caters to a niche market seeking natural and holistic treatment options. By diversifying its product portfolio to include these categories, Hatay Pharmaceutical Joint Stock Company demonstrates responsiveness to evolving consumer preferences and market trends.

2Sourcing Profile

Hatay Pharmaceutical Joint Stock Company's sourcing strategy is characterized by a focus on finished pharmaceutical formulations, particularly those manufactured in India. The company's preference for Indian suppliers is likely due to the country's established reputation for producing high-quality generic medications at competitive prices. This sourcing approach enables Hatay Pharmaceutical Joint Stock Company to offer a diverse range of pharmaceutical products to the Vietnamese market.

The company's emphasis on specific therapeutic areas, such as diabetes and endocrine treatments, suggests a targeted procurement strategy aimed at addressing prevalent health concerns in Vietnam. By aligning its sourcing profile with market demand, Hatay Pharmaceutical Joint Stock Company enhances its competitiveness and relevance in the Vietnamese pharmaceutical sector.

Seller's Guide — How to Become a Supplier to Hatay Pharmaceutical Joint Stock CO

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Hatay Pharmaceutical Joint Stock Company, particularly in the therapeutic areas of diabetes and endocrine treatments, as well as Ayurvedic and herbal products. The company's existing focus on these categories indicates a potential openness to expanding its supplier base to include additional products that meet the needs of the Vietnamese market.

Indian exporters can identify gaps in Hatay Pharmaceutical Joint Stock Company's current sourcing by analyzing the specific formulations and product types that are underrepresented. By offering high-quality alternatives or complementary products, exporters can position themselves as valuable partners. Establishing relationships with the company would require demonstrating product efficacy, compliance with Vietnamese regulatory standards, and the ability to meet supply chain requirements.

2Requirements & Qualifications

Indian exporters seeking to supply Hatay Pharmaceutical Joint Stock Company and the broader Vietnamese market must adhere to several requirements. These include obtaining GMP certifications from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S). Compliance with these standards ensures that products meet international quality benchmarks.

Frequently Asked Questions — Hatay Pharmaceutical Joint Stock CO

What products does Hatay Pharmaceutical Joint Stock CO import from India?

Hatay Pharmaceutical Joint Stock CO imports 2 pharmaceutical products across 2 categories. Top imports: Insulin ($1.0M), Taila ($207.8K).

Who supplies pharmaceuticals to Hatay Pharmaceutical Joint Stock CO from India?

Hatay Pharmaceutical Joint Stock CO sources from 16 verified Indian suppliers. The primary supplier is Wockhardt Limited (71.2% of imports, $3.4M).

What is Hatay Pharmaceutical Joint Stock CO's total pharmaceutical import value?

Hatay Pharmaceutical Joint Stock CO's total pharmaceutical import value from India is $1.2M, based on 26 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hatay Pharmaceutical Joint Stock CO focus on?

Hatay Pharmaceutical Joint Stock CO imports across 2 categories. The largest: Diabetes & Endocrine (82.8%), Ayurvedic & Herbal Products (17.2%).

Get Full Hatay Pharmaceutical Joint Stock CO Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Hatay Pharmaceutical Joint Stock CO

Hatay Pharmaceutical Joint Stock CO — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Hatay Pharmaceutical Joint Stock CO?

What Formulations Does Hatay Pharmaceutical Joint Stock CO Import?

What Products Does Hatay Pharmaceutical Joint Stock CO Import?

Top Products by Import Value

Hatay Pharmaceutical Joint Stock CO Therapeutic Categories — 2 Specializations